Stroke Genetics Update: 2011

Current Cardiovascular Risk Reports

Volumn 5, Issue 6, 2011, Pages 533-541

  Cole, John W ^a   Meschia, James F ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Genetics; Genome wide association studies; Stroke

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; WARFARIN;

ANEURYSM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ARTERY ANEURYSM; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; CHROMOSOME 9P; CLINICAL TRIAL (TOPIC); FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS (TOPIC); MUSCLE CRAMP; MYOPATHY; PHARMACOGENOMICS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SUBARACHNOID HEMORRHAGE;

EID: 84873564262     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-011-0200-6     Document Type: Review

References (59)

1. Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engström G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke. 2007; 38: 2681-5.
2. Baird AE. Genetics and genomics of stroke: novel approaches. J Am Coll Cardiol. 2010; 56: 245-53.
3. http://www. nhlbi. nih. gov/resources/docs/06a_ip_chtbk. pdf.
4. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999; 30: 736-43.
5. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005; 366: 1773-83.
6. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial: TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35-41.
7. Brass LM, Page WF, Lichtman JH. Stroke in twins III: a follow-up study (Abs). Stroke 1998: 29.
8. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000; 123: 1784-812.
9. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004; 35: 819-24.
10. MacClellan LR, Mitchell BD, Cole JW, et al. Familial aggregation of ischemic stroke in young women: The Stroke Prevention in Young Women Study. Gen Epid. 2006; 7: 602-8.
11. • Seshadri S, Beiser A, Pikula A, Himali JJ, Kelly-Hayes M, Debette S, et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation 2010; 121: 1304-12. This is a detailed, community-based prospective study that demonstrated parental stroke by 65 years of age was associated with a threefold increase in risk of offspring stroke, even when adjusting for conventional stroke risk factors. As such, verified parental stroke may serve as a clinically useful risk marker of an individual's propensity to stroke.
12. Lawson KD, Fenwick EA, Pell AC, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage using a cross-sectional survey of 3921 people. Heart. 2010; 96: 208-12.
13. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002; 33: 1190-5.
14. Kissela BM, Sauerbeck L, Woo D, et al. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke. 2002; 33: 1321-6.
15. Meschia JF, Brott TG, Brown Jr RD. Genetics of cerebrovascular disorders. Mayo Clin Proc. 2005; 80: 122-32.
16. • Woo D, Khoury J, Haverbusch MM, et al. Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. Neurology 2009; 72: 69-72. This study provides evidence that a gene-environment interaction with smoking exists for aneurysmal subarachnoid hemorrhage. This finding is important when counseling family members and when considering familial screening for intracranial aneurysms.
17. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genome-wide association analysis of coronary artery disease. New Engl J Med. 2007; 357: 443-53.
18. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007; 316: 1491-3.
19. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007; 316: 1488-91.
20. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke. 2008; 39: 1586-9.
21. • Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, Ross-Adams H, et al. Sequence variants on chromosome 9p21. 3 confer risk for atherosclerotic stroke. Ann Neurol. 2009; 65: 531-9. This study demonstrated that the chromosome 9p21. 3 region, which had previously been associated with coronary artery disease, also represents a major risk locus for atherosclerotic stroke. The study also demonstrated that the effect of this locus on stroke appears to be independent of its relation to coronary artery disease and other stroke risk factors.
22. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008; 40: 217-24.
23. Musunuru K, Post WS, Herzog W, Shen H, O'Connell JR, McArdle PF, et al. Association of single nucleotide polymorphisms on chromosome 9p21. 3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet. 2010; 3: 445-53.
24. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, et al. Functional analysis of the chromosome 9p21. 3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009; 29: 1671-7.
25. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. Nature. 2011; 470: 264-8.
26. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Nature. 2010; 464: 409-12.
27. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996; 383: 707-10.
28. Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010; 41: 630-4.
29. Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, van Agtmael T, et al. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology. 2009; 73: 1873-82.
30. Wiebers DO, Whisnant JP, Huston III J, Meissner I, Brown Jr RD, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003; 362: 103-10.
31. Chinnery PF, Elliott HR, Syed A, Rothwell PM. Mitochondrial DNA haplogroups and risk of transient ischaemic attack and ischaemic stroke: a genetic association study. Lancet Neurol. 2010; 9: 498-503.
32. Anderson CD, Biffi A, Rahman R, Ross OA, Jagiella JM, Kissela B, et al. Common mitochondrial sequence variants in ischemic stroke. Ann Neurol. 2011; 69: 471-80.
33. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984; 16: 481-8.
34. Yoneda M, Ikawa M, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, et al. In vivo functional brain imaging and a therapeutic trial of l-arginine in MELAS patients. Biochim Biophys Acta. 2011, May 8. doi: 10. 1016/j. bbagen. 2011. 04. 018.
35. Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010; 68: 934-43.
36. Matarín M, Brown WM, Scholz S, et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 2007; 6: 414-20.
37. -8).
38. •• Rosand J, Meschia JF, Singleton AB. Failure to validate association between 12p13 variants and ischemic stroke. New Engl J Med. 2010; 362: 1547-50. This is a well-powered meta-analyses consisting of numerous ischemic stroke case-control populations that did not validate the previously reported associations between two SNPs and stroke at the 12p13 locus as reported by Ikram et al. [37••].
39. Lotta LA, Giusti B, Saracini C, Vestrini A, Volpe M, Rubattu S, et al. No association between chromosome 12p13 single nucleotide polymorphisms and early-onset ischemic stroke. J Thromb Haemost. 2010; 8: 1858-60.
40. Olsson S, Melander O, Jood K, Smith JG, Lovkvist H, Sjogren M, et al. Genetic variant on chromosome 12p13 does not show association to ischemic stroke in 3 Swedish case-control studies. Stroke. 2011; 42: 214-6.
41. Matsushita T, Umeno J, Hirakawa Y, Yonemoto K, Ashikawa K, Amitani H, et al. Association study of the polymorphisms on chromosome 12p13 with atherothrombotic stroke in the Japanese population. J Hum Genet. 2010; 55: 473-6.
42. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative classification of stroke system. Stroke. 2007; 38: 2979-84.
43. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005; 58: 688-97.
44. • Arsava EM, Ballabio E, Benner T, Cole JW, Delgado-Martinez MP, Dichgans M, et al. The Causative classification of stroke system: an international reliability and optimization study. Neurology 2010; 75: 1277-84. This article describes how a new stroke classification system, the CCS, allows classification of stroke subtypes by multiple investigators with high reliability, thereby supporting its potential for improving stroke classification in multicenter studies. The CCS is hoped to alleviate some of the ambiguities generated by the widely-employed TOAST classification system.
45. Kitzmiller JP. Pharmacogenomic testing: relevance in medical practice. Cleve Clin J Med. 2011; 78: 243-57.
46. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501.
47. Heneghan C, Tyndel S, Bankhead C, Wan Y, Keeling D, Perera R, et al. Optimal loading dose for the initiation of warfarin: a systematic review. BMC Cardiovasc Disord. 2010; 10: 18.
48. • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009; 361: 1139-51. Although not a genetics study, this large randomized study demonstrated that in patients with atrial fibrillation, dabigatran as compared with warfarin was associated with lower rates of stroke and systemic embolism. On the basis of this trial, dabigatran is now approved for stroke prevention in the setting of atrial fibrillation in the United States.
49. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123: 1436-50.
50. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010; 122: 394-403.
51. Ferreiro JL, Ueno M, Tomasello SD, Capodanno D, Desai B, Dharmashankar K, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011; 4: 273-9.
52. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006; 97(Suppl): 52C-60C.
53. Armitage J. The safety of statins in clinical practice. Lancet. 2007; 370: 1781-90.
54. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. New Engl J Med. 2008; 359: 789-99.
55. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. N Schmied Arch Pharmacol. 2006; 372: 432-43.
56. Walford GA, Florez JC. Type 2 diabetes and genetics, 2010: translating knowledge into understanding. Curr Cardiovasc Risk Rep. 2010; 4: 437-45.
57. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40: 189-97.
58. MacArthur D. Why do genome-wide scans fail? Genetic Future 2008. http://www. genetic-future. com/2008/03/why-do-genome-wide-scans-fail. html.
59. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet. 2008; 40: 695-701.